We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Amnestix Develops Genetic Analysis System
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Diagnostics > Amnestix Develops Genetic Analysis System
DiagnosticsTechnology

Amnestix Develops Genetic Analysis System

HerinaAyot
HerinaAyot
Share
1 Min Read
SHARE

Amnestix is a biopharmaceutical company that has developed a powerful analytical platform to identify genetic determinants that underlie neurological disorders. The company’s genetic analysis system is called whole-genome association, and functions by comparing the genome of healthy and ill patients at hundreds of thousands of positions in order to identify where disease-prone genomes differ from healthy genomes. The company has used its technology to identify a bioactive protein essential for memory function, termed KIBRA.

Amnestix is a biopharmaceutical company that has developed a powerful analytical platform to identify genetic determinants that underlie neurological disorders. The company’s genetic analysis system is called whole-genome association, and functions by comparing the genome of healthy and ill patients at hundreds of thousands of positions in order to identify where disease-prone genomes differ from healthy genomes. The company has used its technology to identify a bioactive protein essential for memory function, termed KIBRA. The company is currently developing therapeutics targeting KIBRA which are indicated to treat acute memory loss, as seen in Alzheimer’s disease. The company’s analytical platform is currently being used to study other neurological disorders, including schizophrenia.

 

TAGGED:Amnestixmedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

A Mobile Imaging Efficiency Showdown: CR vs. DR [VIDEO]

July 26, 2014

Shorter Wait in the ER Just a Click Away with Startup’s Virtual Waiting Service

July 7, 2013

Visions of Care

August 20, 2014

Drug Dispensing Robot at Hospital Pharmacy

March 13, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?